Drs. Yashdeep Phanse and Adel Talaat recently received a Phase I SBIR grant from the United States Department of Agriculture (USDA) to further develop and commercialize their novel Infectious Bronchitis virus (IBV) vaccine. Infectious Bronchitis (IB) is an economically important severe respiratory infectious disease of poultry caused by an avian coronavirus, IBV. The USA animal state health report identifies IBV as a critical source of economic loss in the broiler and egg laying industry. There is significant room for improvement in current vaccines available for IBV. Innovative technologies that can address the tremendous genetic variation of IBV and the poor cross- reactive immunity induced by conventional vaccines are desperately needed. PGS’ proprietary vaccine technology can overcome these problems and can ultimately lead to a safe, easy-to-dose, highly effective and broadly reactive IBV vaccine.